Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study
Sickle cell disease (or simply, SCD) is an inherited hemoglobinopathy which is mostly prevalent among persons of African descent. SCD results from a monogenic (Hemoglobin, beta) point-mutation (substitution of the base Adenine with Thymine at position six) that leads to replacement of the amino acid glutamic acid (E) with valine (V). Management of SCD within resource-poor settings is largely syndromic, since the option of cure offered by bone-marrow transplantation (BMT) is risky and unaffordable by most affected individuals. Despite previous reports of repair and inhibition of the sickle beta-globin gene and messenger ribonucleic acids (mRNAs), respectively in erythrocyte precursor cells via gene-targeting using an oligomer-restriction enzyme construct and either ribozyme- or RNA-DNA chimeric oligonucleotides (or simply third strand binding), gene-therapy to treat SCD still remains largely preclinical. In the wake of the advances in target- gene- mutagenesis and repair wrought by zinc finger nuclease (ZFN) technology, it was hypothesized that SCD may be cured by the same. The goal of this study thus, was constructing a database of zinc finger arrays (ZFAs) and engineering ZFNs, that respectively bind and cleave within or around specific sequences in the sickle hemoglobin, beta (−βS) gene.
Methods and results
First , using the complete 1606 genomic DNA base pair (bp) sequences of the normal hemoglobin-beta (βA) chain gene, and the ZiFiT-CoDA-ZFA software preset at default, 57 three-finger arrays (ZFAs) that specifically bind 9 base-pair sequences within the normal hemoglobin-beta chain, were computationally assembled. Second , by serial linkage of these ZFAs to the Flavobacterium okeanokoites endonuclease Fok I― four ZFNs with unique specificity to >24 bp target-sequences at the genomic contextual positions 82, 1333, 1334, and 1413 of the βA chain-gene were constructed in-silico. Third , localizing the point-mutation of SCD at genomic contextual position −69-70-71- bp (a position corresponding to the 6th codon) of the βA chain-gene, inspired the final design of five more ZFNs specific to >24 bp target-sequences within the 8,954 bp that are genomically adjacent to the 5′ end of the βA chain-gene.
This set of 57 ZFAs and 9 ZFNs offers us gene-therapeutic precursors for the targeted mutagenesis and repair of the SCD mutation or genotype.
KeywordsSickle Cell Disease Sickle Cell Sickle Cell Trait Zinc Finger Nuclease Beta Gene
Sickle cell diseases (SCD) or sickle cell anemia (SCA) is a hemoglobinopathy that is mostly common among persons of African descent . SCD arises from a single, point-mutation (base-substitution of Adenine with Thymine in the sixth codon: CAG → CTG) of the gene coding for the beta chain of the Hemoglobin molecule . The phenotypic consequence of this substitution is a replacement of the amino acid glutamic acid (E) with valine (V) [1, 2]. Homozygous expression of this mutant globin genotype (SS) causes SCD, while the heterozygous genotype (AS) is termed the “sickle cell trait” [1, 2]. Unlike the case observed in most normal adult humans where the commonest hemoglobin type (hemoglobin A or Hb A) is a tetramer (which contains 4 subunit proteins- α2β2A that are non-covalently bound together), patients with SCD have an adult hemoglobin type with two mutant β subunits (called βS) called hemoglobin S (or simply, Hb S) [3, 4]. Hb S has a high predilection to crystallize under conditions of low oxygen-pressure such as may occur following physical or pathological-stress. Specifically, formation of intracellular S crystals causes polymerization of red blood cells, reduced oxygen uptake and or carriage, a as well as clogging of small blood vessels [5, 6]. Overall, although the clinical syndrome of SCD is diversely-wide, its hallmark is a devastating group of symptoms and signs that are collectively known as a ‘sickle cell crisis’ [7, 8]. About 200,000 new born babies within Africa recessively inherent the double autosomal-sickle cell genotype each year— a figure that constitutes approximately 66.6% of the children born with haemoglobinopathies worldwide . Previously studies have shown that persons with heterozygosity for βS (Hb SA) or the sickle cell trait are protected against infection by malaria causing protozoa . This, together with findings of an equally high-incidence or common-distribution of the sickle cell trait within the malaria-belt, has led to the proposition that this trait emerged as an evolutionary adaptation of the human-host to infection with plasmodia . The medical management of SCD remains an area of particular challenge . Specifically, despite advances made towards curing SCD through bone-marrow transplantation [13, 14], the resource-intensive nature of this approach has made it impossible for the most affected populations of Africa to access. Thus, care for affected individuals (homozygous SS) here still mostly revolves around syndromic management, with or without agents that increase fetal hemoglobin (Hb F) . Improvements are obviously sought here.
By virtue of its monogenic, point-mutant origin, SCD has attracted several attempts for gene therapy. For instance, as early as 1991, Shesely ED, et al. described a technique for the correction of a human βS globin gene to the normal βA allele by homologous recombination in the mouse-human hybrid cell line BSM using an oligomer-restriction enzyme construct. In 1998, Lans N, et al.[17, 18] reported ribozyme mediated deletion and augmentation of the sickle-cell (βS) mutation with fetal haemoglobin levels in the red cells. Selective inhibition of beta-globin RNA transcripts by antisense RNA molecules has equally been tried as a strategy to reduce levels of Hb S polymerization in red blood cells and the symptoms associated with SCD [19, 20, 21]. Pace BS, et al. specifically identified antisense RNA targets in the beta-globin gene other than the homologous regions in gamma-globin, proposing that gene therapy strategies which combine gamma-globin induction along with beta-globin inhibition using antisense vectors may yield more favorable anti-sickling effects longterm. Amosova O, et al.,on the other hand, reported third-strand directed repair of the sickle cell mutation using RNA-DNA chimeric oligonuceotides (COs) [23, 24] achieved by shortening the psoralen linker to enhance the specificity of photoadduct formation at the desired mutant T residue site. Despite these notable advances, the place for gene-replacement or repair therapy in SCD has remained rather experimental , with no clinical trials of any of the above approaches in human populations yet reported.
Basing on the more-recent developments in targeted mutagenesis (genome-editing) and gene-repair wrought by zinc finger nuclease (ZFN) technology [26, 27, 28, 29, 30, 31, 32], it was hypothesized that the single, point mutation responsible for SCD can be abrogated using similar approaches. Specifically, Zinc finger nucleases-ZFNs, which are artificial, hybrid restriction enzymes created by covalently linking a DNA-binding zinc finger (Zif) domain (composed of three to six finger-arrays) to the non-specific DNA cleavage domain (or simply FN) of the Flavobacterium okeanokoites bacteria restriction endonuclease, FokI ; have recently become a powerful tool for primarily editing host genomes. Following induction of a double strand break (DSB) within the target DNA, repair occurs, either by homologous recombination (HR) or non-homologous end-joining (NHEJ) [26, 27, 28, 29, 30, 31, 32]. Perez et E al. -using engineered ZFNs targeting human CCR5, previously demonstrated establishment of HIV-1 resistance in CD4+ T cells through generation of a doublestrand break (DSB) at predetermined sites in the CCR5 coding region upstream of the natural CCR5D32 mutation. Holmes N et al.  have demonstrated control of HIV-1 infection within NSG-mice transplanted with human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeting CCR5. Most recently, Wilen CB, et al. successfully engineered HIV-Resistant Human CD4+ T Cells using CXCR4-Specific Zinc-Finger Nucleases (ZFN). This evidence, along with on-going improvements in the design and engineering of lentiviral [33, 34] and parvovirus  vectors (LV and PV, respectively) for ex-vivo or in-vivo gene-delivery and transduction of erythroid precursors, suggests that the sickle cell mutation may be abrogated in erythroid bone marrow precursor with appropriate ZFNs. Indeed, we are aware that Sangamo Biosciences (http://www.sangamo.com/index.html)--one of the leading industries in ZFN-technology, has already focused its ZFN-mediated gene-editing technology to providing a unique solution for the treatment of monogenic diseases like hemophilia and SCA. Their ZFAs or ZFNs are, however, not publically available.
Thus, the specific goal of this study was to construct a database of zinc finger arrays (ZFAs) and engineer ZFNs that respectively specifically bind and cleave within or around the sickle hemoglobin beta (−βS) gene mutation.
Identification of HBB gene-specific ZFAs and ZFNs
No in-vivo or in-vitro experiments accompanied this bioinformatics study, and thereby no ethical approval and Consent was sought from the author’s institutional IRB.
Materials and software
FASTA format of the nucleotide sequences of the entire Hemoglobin, beta-gene (provided in Additional file 1; the NCBI accession number provided at end) and the Zinc-Finger Nuclease-Consortium’s software CoDA-ZiFiT-ZFA and CoDA-ZiFiT-ZFN [36, 37] (see software and availability section for URL link).
The FASTA format of the nucleotide sequences of the hemoblobin, beta gene were separately fed into the user interfaces of CoDA-ZiFiT-ZFA and the CoDA-ZiFiT-ZFN, both of which were pre-set at default, with a spacer-option of 5–9 bp selected for the latter.
Lists of ZFAs and ZFNs, inclusive of graphic maps of their action in the genomic context of HB, beta, were generated as per the user protocol [36, 37]. Another array of five ZFNs specific to >24 bp target-sequences within the adjacent 8,954 bp to the 5′ end of the βA chain-gene; was also engineered.
Software and database availability
The ZFN consortium CoDA-ZiFiT-ZFA/ZFN software and algorithms used are available at the following url: http://www.zincfingers.org/scientific-background.htm
The NCBI gene database hosting the HBB gene, is available at the following url: http://www.ncbi.nlm.nih.gov/gene/3043
Zinc Finger Arrays (ZFAs) targeting hemoglobin, beta (βA) gene sequences
Zinc Finger Nucleases (ZFN) targeting hemoglobin, beta (βA) gene sequences
Table 1 ZFN targeting and cleaving within the hemoglobin, beta ( β A )-gene
Zinc Finger Nuclease (ZFN)
Left Fn; triplet- α-Helix
Right Fn; triplet- α-Helix
-targeting HBB ( βA)-DNA at 5′ Sites
5′_82 cCGTTACTGCCCTGTGGGGCAAGGt 106_′3
F1; RNITLVR; (ACG)
F1; RNEHLKV; (AGG)
5′_82 gGCAATGACGGGACACCCCGTTCCa 106_′3
F2; QRSSLVR; (GTA)
F2; QSTTLKR; (GCA)
F3; QDNTLRR; (GCA)
F3; RTEHLAR; (GGG)
-targeting HBB ( β A )-DNA at 3′ Sites
5′_1333 cTTCCTCCCACAGCTCCTGGGCAACGt 1359_′3
F1; QASNLLR; (GAA)
F1; RSQTLAQ; (ACG)
5′_1333 gAAGGAGGGTGTCGAGGACCCGTTGCa 1359_′3
F2; RQDNLGR; (GAG)
F2; QSTTLKR; (GCA)
F3; RMDHLAG; (TGG)
F3; RSDHLSL; (TGG)
5′_1334 tTCCTCCCACAGCTCCTGGGCAACGt 1359_′3
F1; RTDRLIR; (GGA)
F1; RSQTLAQ; (ACG)
5′_1334 aAGGAGGGTGTCGAGGACCCGTTGCa 1359_′3
F2; QSAHLKR; (GGA)
F2; QSTTLKR; (GCA)
F3; RNTALQH; (GTG)
F3; RSDHLSL; (TGG)
Zinc Finger Nucleases (ZFN) targeting within the adjacent 8,954 bp to the 5′ end of the βA chain-gene
Table 2 ZFN targeting and cleaving within the adjacent 8,954 bp to the 5′ end of the hemoglobin, beta ( β A )-gene
Zinc Finger Nuclease (ZFN)
Left Fn; triplet- α-Helix
Right Fn; triplet- α-Helix
5′_4231 aGCCACCACCTTCT GATAGGCAGCCt 4256_′3
F1; VPSKLKR; (GGC)
F1; DPSTLRR; (GCC)
5′_4231 tCGGTGGTGGAAGA CTATCCGTCGGa 4256_′3
F2; EAHHLSR; (GGT)
F2; QSTTLKR; (GCA)
F3; IRHHLKR; (GGT)
F3; RRDGLAG; (TAG)
5′_4234 cACCACCTTCTGAT AGGCAGCCTGCa 4259_′3
F1; MKHHLAR; (GGT)
F1; RGRNLEM; (TGC)
5′_4234 gTGGTGGAAGA CTATCCGTCGGACGt 4259_′3
F2; EAHHLSR; (GGT)
F2; DSSVLRR; (GCC)
F3; QDGNLTR; (GAA)
F3; QGGTLRR; (GCA)
Discussion and conclusions
I present here a novel set of 57 zinc finger arrays (ZFAs) and 9 zinc finger nucleases (ZFNs) ― that constitute gene-therapeutic precursors for the targeted mutagenesis and repair of the SCD mutation or genotype. Specifically, although SCD results from a monogenic (Hemoglobin, beta) point-mutation (substitution of A with T) that has attracted extensive interest for target gene-therapy [16, 17, 18, 19, 20, 21, 22, 23, 24, 25], the place for gene-replacement or repair therapy in SCD has remained rather experimental , and no clinical trials of any of the above approaches in human populations are yet to be reported. Basing on the more-recent developments in targeted mutagenesis (genome-editing) and gene-repair wrought by zinc finger nuclease (ZFN) technology [26, 27, 28, 29, 30, 31, 32], it was hypothesized that the single, point mutation responsible for SCD can be abrogated using similar approaches. To this end, we sought to construct a database of zinc finger arrays (ZFAs) and engineer ZFNs that specifically bind and cleave within or around the sickle hemoglobin, beta (−βS) gene. Now, we present a database of 57 ZFAs (see, Additional file 2 and Figure 1) specific to the βA gene (see,Additional file 1 for genomic contextual sequences). Using these ZFAs, we also constructed four ZFNs (shown in Additional file 3 and Figure 2) cleaving specifically within the same βA gene. Three of these four ZFN are shown in Table 1. Because the point-mutation of SCD is located at genomic contextual position −69-70-71- bp of the βA chain-gene sequences used (that is, within the 6th codon of the gene), we were equally inspired to design another array of five ZFNs (shown in Additional file 5) specific to >24 bp target-sequences within the adjacent 8,954 bp to the 5′ end of the βA chain-gene (seeAdditional file 4 for the 8,954 bp localized to the 5′ end of the βA chain-gene). Two of the ZFN cleaving within these- 8,954 bp but closest to the 5′ end of the βA chain-gene, are shown in Table 2, while Figure 3 offers a graphic summary of their distribution.
The above ZFAs and ZFNs may be applied towards the target mutagenesis or repair of the sickle cell mutation, in various ways. Firstly, splicing out the entire genomic region located between positions 5′-82/106, and 3′ -1,333/1,359 or −1,334/1,359 of the βS globin gene may be achieved using the ZFNs shown in Table 1. This alone― when followed by the process of non-homologous end-joining (NHEJ) [26, 27, 28, 29, 30, 31, 32] of the residual double strand DNA break (DSB)’s edges could lead to deletion of over 80% bp-sequences of the defective βS globin gene. Depending on the efficiency of the gene-delivery and transduction achieved by the vectors [34, 35] used within erythroid precursors, therefore, this strategy alone offers the possibility of reducing the intracellular (either mature red blood cell, RBC or erythroid precursor) expression of the βS globin gene, and ultimately curtailing the symptomatology resulting from S polymerization. Note that, because this approach does not involve deletion of the SCD point-mutation which is located at genomic contextual position −69-70-71- bp of the βA chain-gene sequences used (that is, within the 6th codon of the gene), it is only a means to functionally irreversibly inactivate the βS globin gene. Thus, as a second option, another may purpose to delete the 5′ region before position −82/106 of the βS globin gene, which contains the point-mutation of SCD. This can be achieved using the ZFN in Table 1 that cleaves at position 82/106 and any of the two ZFNs in Table 2 that cleave within the 8,954 bp localized to the 5′ end of the βA chain-gene. Alternatively, however, secondary therapeutic events, including say (i) either repair of the target βS globin gene cleavage-site by either recruiting the homologous recombination (HR) pathway through providing a normal, non-mutant β globin gene template for repair of the spliced ‘mutant (disease causing)’ region [26, 27, 28, 29, 30, 31, 32, 36, 37] (ii) or supplementary replacement of this pathogenic-spliceon with a corresponding 5′ exon of γ-globin in a similar way as Lans N, et al. and Weatherall DJ.  did with a 3′ exon, may be sought. Pace BS, et al. has proposed that gene therapy strategies which combine gamma-globin induction along with beta-globin inhibition may yield more favorable anti-sickling effects in the longterm. Lastly, perhaps completely novel gene-therapeutic strategies devised in future may equally explore the target-DNA-binding mechanisms inherent in our ZFAs or ZFN to repair the mutant codon of the βS globin gene.
In conclusion, this set of 57 zinc finger arrays (ZFAs) and 9 zinc finger nucleases (ZFNs) ― offers us gene-therapeutic precursors for the targeted mutagenesis and repair of the SCD mutation or genotype. Specifically, the same may be used to either functionally or structurally abrogate the βS globin gene. Alternatively, supplementary replacement of this pathogenic-spliceon with a corresponding 5′ exon of γ-globin may be possible. Lastly, novel gene-therapeutic strategies devised in future may equally explore the target-DNA binding and cleaving mechanisms inherent in our ZFAs or ZFN to replace or repair the mutant codon of the βS globin gene.
The NCBI gene identity of the Hemoglobin, beta gene is |3043|; whereas the NCBI reference for the 8.95 kb region from base 5190000 to 5198951 is |NT_009237.18|
WM is supported by Grant Number 5R24TW008886 OGAC, NIH and HRSA. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the supporting offices.
- 8.Dunlop RJ, Bennett KC: Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006, 19 (2): CD003350-Google Scholar
- 14.Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM: Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000, 95 (6): 1918-1924.PubMedGoogle Scholar
- 19.Alami R, Gilman JG, Feng YQ, Marmorato A, Rochlin I, Suzuka SM, Fabry ME, Nagel RL, Bouhassira EE: Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia. Blood Cells Mol Dis. 1999, 25 (2): 110-119. 10.1006/bcmd.1999.0235.CrossRefPubMedGoogle Scholar
- 21.Pace BS, Qian X, Ofori-Acquah SF: Selective inhibition of beta-globin RNA transcripts by antisense RNA molecules. Cell Mol Biol (Noisy-le-grand). 2004, 50 (1): 43-51.Google Scholar
- 22.Amosova O, Broitman SL, Fresco JR: Repairing the Sickle Cell mutation. II. Effect of psoralen linker length on specificity of formation and yield of third strand-directed photoproducts with the mutant target sequence. Nucleic Acids Research. 2003, 31 (16): 4673-4681. 10.1093/nar/gkg659.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Wayengera M: Bone marrow transplantation (BMT) and gene replacement therapy (GRT) in sickle cell anemia. Niger J Med. 2008, 17 (3): 251-256.Google Scholar
- 31.Perez E, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008, 26 (7): 808-816. 10.1038/nbt1410.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM: Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010, 28 (8): 839-847. 10.1038/nbt.1663.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan APO1, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, Hoxie JA, Danet-Desnoyers GA, Bushman FD, Riley JL, Gregory PD, June CH, Holmes MC, Doms RM: Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. PLoS Pathog. 2011, 7 (4): e1002020-10.1371/journal.ppat.1002020.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P: Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010, 467 (7313): 318-322. 10.1038/nature09328.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Herrmann F, Garriga-Canut M, Baumstark R, Fajardo-Sanchez E, Cotterell J, Minoche A, Himmelbauer H, Isalan M: p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing. PLoS One. 2011, 6 (6): e20913-10.1371/journal.pone.0020913.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, Holmes MC, Gregory PD, Glimm H, Schmidt M, Naldini L, von Kalle C: An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. 2011, 29 (9): 816-823. 10.1038/nbt.1948.CrossRefPubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2326/12/5/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.